#1

The bad thing is that post Brexit, it seems that the MHRA has gotten a bit backlogged and isn’t able to keep up with our current demands on their time. It takes too long to get meetings and responses to applications currently. We’ve had to take our first human clinical trial to Australia, where it’s a faster, more streamlined, and cheaper process.

I think Insilico has opened an office in the middle east (don’t remember the country). I can see some countries deciding that testing drugs could be a growth industry for them.

4 Likes
#2

They’re in Abu Dhabi, UAE :united_arab_emirates:.

Australia did a good job at streamlining processes for trials.

But the real winner is China. That’s where the innovation happens now: x.com

1 Like
#3

"Cyclodextrins, the core chemical structure of UDP-003, are cyclic sugar-based molecules capable of encapsulating lipophilic compounds such as cholesterol. While some forms of cyclodextrins have been used as excipients or in experimental cholesterol efflux therapies, the dimeric structure of UDP-003 confers around 1,000-fold greater selectivity for 7KC over cholesterol, according to the authors [1].

This selectivity appears to be central to the compound’s ability to remove 7KC from human atherosclerotic plaque tissue in as little as 15 minutes, and to promote urinary excretion of the toxin in vivo. Notably, these effects occurred without significant toxicity; UDP-003 has completed a suite of preclinical safety studies and is now considered ready for clinical development."

1 Like